Immunomedics Announces U.S. Patent for Hexavalent DOCK-AND-LOCK Complexes
Immunomedics (Nasdaq: IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, announced that IBC Pharmaceuticals, Inc. (IBC), a majority-owned subsidiary, has received notice that its patent application for "Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases," will issue as U.S. patent no. 8,349,332 today.
This patent, which provides coverage until 2026, concerns methods of use of hexavalent DOCK-AND-LOCK™ (DNL™) constructs, comprising antibodies and/or antigen-binding antibody fragments tethered together using the Company's patented platform technology. The allowed claims cover bispecific antibodies that bind to CD20 and CD22 antigens on B cells. The DNL™ complexes are of use for the treatment of B-cell malignancies or B-cell-related autoimmune diseases.
At the 2012 Annual Meeting of the American Society of Hematology, the Company reported potent anti-tumor activity of a new class of hexavalent bispecific antibodies targeting CD20 and CD22 in an animal model of human non-Hodgkin lymphoma. These DNL™ complexes extended the median survival time of animals in a statistically significant manner. (Please refer to the Company's press release at www.immunomedics.com/pdfs/news/2012/pr12122012.pdf for more information).
"We are pleased to receive this patent. These hexavalent bispecific antibodies are more effective in killing of B cells, even in the absence of cross-linking antibodies, by inducing multiple signaling pathways in the target cell," commented Cynthia L. Sullivan, President and Chief Executive Officer. "We believe that these next-generation bispecific antibodies may contain the therapeutic properties of both CD20 and CD22 antibodies in a single construct, thus avoiding administration and costs of two antibodies that appear to show complementary and enhanced activity when combined," Ms. Sullivan further remarked.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.